A Phase 1 interventional study of Alvocidib and Cytarabine in Acute Myeloid Leukemia, sponsored by Sumitomo Pharma America, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-15.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing alvocidib in Leukemia, Myeloid, Acute — none open to participants now, none under way, none of them phase 3. alvocidib · Leukemia, Myeloid, Acute.
Among the 12 studies testing alvocidib in Leukemia, Myeloid, Acute, this one is the 9th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 1, and was the 9th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →None of the 12 studies testing alvocidib in Leukemia, Myeloid, Acute is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7
First in 2004; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 41 across the 12 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
Sumitomo Pharma Co., Ltd. has 8 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing alvocidib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase I study is to determine the safety and tolerability including the maximum dose (MTD) and dose-limiting toxicities (DLTs) of alvocidib when administered over a range of doses on Days 1-3 followed by cytarabine/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed and previously untreated AML
Primary Objective:
Secondary Objectives:
Exploratory Objective:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for participation in the study, patients must meet all of the following inclusion criteria:
Exclusion Criteria:
Patients meeting any one of these exclusion criteria will be prohibited from participating in this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The starting dose of alvocidib will be 20 mg/m2 as a 30-minute intravenous (IV) bolus followed by 30 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3 of Induction. Patients will have a one day drug holiday (Day 4) before initiation of the 7+3 regimen. Beginning on Day 5, cytarabine will be administered as a 100 mg/m2/day continuous IV infusion for seven consecutive days (Days 5-11) plus daunorubicin administered at a dosage of 60 mg/m2 IV on Days 5-7.
Drug: Alvocidib · Drug: Cytarabine · Drug: Daunorubicin
IV bolus followed by IV infusion
continuous infusion
IV bolus
Maximum Tolerated Dose (MTD) of Alvocidib
Determine the safety and tolerability including the maximum tolerated dose (MTD) of alvocidib when administered over a range of doses on Days 1-3 followed by Ara-c/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed and previously untreated AML
Time frame: During the first cycle
Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib
Determine the safety and tolerability including dose-limiting toxicities (DLTs) of alvocidib when administered over a range of doses on Days 1-3 followed by Ara-c/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed and previously untreated AML
Time frame: During the first cycle
Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria
CR: Measurable residual disease is positive or unknown; BM blasts (bls) \<5%; no circulating bls and bls w/ Auer rods; no extramedullary disease; ANC \>1.0 x 109/L; platelets \>100 x 109/L. CRMRD-: CR w/ negativity genetic marker. CRi: CR except residual neutropenia or thrombocytopenia. MLFS: BM bls \<5%; no bls with Auer rods; no extramedullary disease; no hematologic recovery required. PR: all hematologic CR criteria; decrease (dec) BM bls % to 5-25%; dec pretreatment BM bls % by \>50%. SD: no CRMRD-/CR/CRi/PR/MLFS; PD criteria not met. PD: increase (inc) BM bls % and/or inc absolute bls in blood: 50% inc BM bls over baseline (\>15% point inc required in cases w/ \<30% bls at baseline or persistent BM bls % of \>70% over at least 3 months; without at least 100% improvement in ANC to absolute level \[\>0.5 x 109/L and/or platelet count to \>50 x 109/L non-transfused); or \>50% inc in peripheral bls to \>25 x 109/L (in the absence of differentiation syndrome); or new extramedullary disease.
Time frame: Best response during duration of study
Recommended Phase 2 Dose (RP2D) of Alvocidib in Combination With 7+3
The dose at which \< 1 of 6 patients experience a DLT during Cycle 1 with the next higher dose having at least 2 of 3 to 6 patients experiencing a DLT during Cycle 1
Time frame: During Cycle 1 beginning at 1st dose of study drug through Day 50 + or - 3 days
Minimal Residual Disease (MRD) Using Standardized Techniques
Percentage of participants with a CRMRD- response at the end of Cycle 1
Time frame: During duration of study
32 patients at 3 sites; Recruitment started 25Sep2017 Recruitment ended 20Mar2020
| Milestone | Alvocidib 20/30 mg/m2 | Alvocidib 30/40 mg/m2 | Alvocidib 30/50 mg/m2 | Alvocidib 30/60 mg/m2 |
|---|---|---|---|---|
| Started | 3 | 3 | 3 | 23 |
| Completed | 2 | 2 | 1 | 8 |
| Not completed | 1 | 1 | 2 | 15 |
| Withdrew: Physician decision | 1 | 0 | 0 | 6 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 | 4 |
| Withdrew: Relapsed disease (following remission) | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 2 |
| Withdrew: Insurance company decision | 0 | 0 | 0 | 1 |
Determine the safety and tolerability including the maximum tolerated dose (MTD) of alvocidib when administered over a range of doses on Days 1-3 followed by Ara-c/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed and previously untreated AML
| mg/m2 | All Participants |
|---|---|
| Bolus | 30 |
| IV infusion | 60 |
Determine the safety and tolerability including dose-limiting toxicities (DLTs) of alvocidib when administered over a range of doses on Days 1-3 followed by Ara-c/daunorubicin (7+3) on Days 5-11 in adults with newly diagnosed and previously untreated AML
| Participants | Alvocidib 20/30 mg/m2 | Alvocidib 30/40 mg/m2 | Alvocidib 30/50 mg/m2 | Alvocidib 30/60 mg/m2 |
|---|---|---|---|---|
| Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib | 0 | 0 | 0 | 1 |
CR: Measurable residual disease is positive or unknown; BM blasts (bls) \<5%; no circulating bls and bls w/ Auer rods; no extramedullary disease; ANC \>1.0 x 109/L; platelets \>100 x 109/L. CRMRD-: CR w/ negativity genetic marker. CRi: CR except residual neutropenia or thrombocytopenia. MLFS: BM bls \<5%; no bls with Auer rods; no extramedullary disease; no hematologic recovery required. PR: all hematologic CR criteria; decrease (dec) BM bls % to 5-25%; dec pretreatment BM bls % by \>50%. SD: no CRMRD-/CR/CRi/PR/MLFS; PD criteria not met. PD: increase (inc) BM bls % and/or inc absolute bls in blood: 50% inc BM bls over baseline (\>15% point inc required in cases w/ \<30% bls at baseline or persistent BM bls % of \>70% over at least 3 months; without at least 100% improvement in ANC to absolute level \[\>0.5 x 109/L and/or platelet count to \>50 x 109/L non-transfused); or \>50% inc in peripheral bls to \>25 x 109/L (in the absence of differentiation syndrome); or new extramedullary disease.
| participants | Alvocidib 20/30 mg/m2 | Alvocidib 30/40 mg/m2 | Alvocidib 30/50 mg/m2 | Alvocidib 30/60 mg/m2 |
|---|---|---|---|---|
| Complete Remission MRD Negative (CRMRD-) | 2 | 0 | 2 | 8 |
| Complete Remission MRD Positive or Unknown (CR) | 1 | 2 | 0 | 7 |
| Partial Remission (PR) | 0 | 1 | 0 | 1 |
| Stable Disease | 0 | 0 | 0 | 2 |
| Progressive Disease (PD) | 0 | 0 | 1 | 4 |
| Not Evaluated | 0 | 0 | 0 | 1 |
The dose at which \< 1 of 6 patients experience a DLT during Cycle 1 with the next higher dose having at least 2 of 3 to 6 patients experiencing a DLT during Cycle 1
| mg/m2 | All Participants |
|---|---|
| Bolus | 30 |
| IV infusion | 60 |
Percentage of participants with a CRMRD- response at the end of Cycle 1
| percentage of participants | Alvocidib 20/30 mg/m2 | Alvocidib 30/40 mg/m2 | Alvocidib 30/50 mg/m2 | Alvocidib 30/60 mg/m2 |
|---|---|---|---|---|
| Minimal Residual Disease (MRD) Using Standardized Techniques | 66.7 | 0 | 66.7 | 34.8 |
Collected over Beginning at 1st dose of study drug through 30 days of the last administration of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alvocidib 20/30 mg/m2 (N=3) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Alvocidib 30/40 mg/m2 (N=3) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Alvocidib 30/50 mg/m2 (N=3) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Alvocidib 30/60 mg/m2 (N=23) | 2/23 (8.7%) | 5/23 (21.7%) | 23/23 (100%) |
| Event | Alvocidib 20/30 mg/m2 (N=3) | Alvocidib 30/40 mg/m2 (N=3) | Alvocidib 30/50 mg/m2 (N=3) | Alvocidib 30/60 mg/m2 (N=23) |
|---|---|---|---|---|
| Cardiogenic shockCardiac disorders | 1/3 | 0/3 | 0/3 | 0/23 |
| FungaemiaInfections and infestations | 1/3 | 0/3 | 0/3 | 0/23 |
| SepsisInfections and infestations | 1/3 | 0/3 | 0/3 | 1/23 |
| Cytokine release syndromeImmune system disorders | 0/3 | 0/3 | 0/3 | 1/23 |
| PneumoniaInfections and infestations | 0/3 | 0/3 | 0/3 | 1/23 |
| Pneumonia fungalInfections and infestations | 0/3 | 0/3 | 0/3 | 1/23 |
| Septic shockInfections and infestations | 0/3 | 0/3 | 0/3 | 1/23 |
| Blood bilirubin increasedInvestigations | 0/3 | 0/3 | 0/3 | 1/23 |
| Blood creatinine increasedInvestigations | 0/3 | 0/3 | 0/3 | 1/23 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 0/3 | 0/3 | 0/3 | 1/23 |
| Event | Alvocidib 20/30 mg/m2 (N=3) | Alvocidib 30/40 mg/m2 (N=3) | Alvocidib 30/50 mg/m2 (N=3) | Alvocidib 30/60 mg/m2 (N=23) |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 3/3 | 2/3 | 3/3 | 19/23 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 3/3 | 3/3 | 23/23 |
| ConstipationGastrointestinal disorders | 0/3 | 2/3 | 3/3 | 5/23 |
| Aspartate aminotransferase increasedInvestigations | 0/3 | 1/3 | 3/3 | 3/23 |
| HypokalaemiaMetabolism and nutrition disorders | 3/3 | 2/3 | 3/3 | 16/23 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/3 | 3/3 | 1/3 | 3/23 |
| NauseaGastrointestinal disorders | 1/3 | 2/3 | 2/3 | 17/23 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/3 | 2/3 | 0/23 |
| ProctalgiaGastrointestinal disorders | 2/3 | 0/3 | 0/3 | 1/23 |
| Oedema peripheralGeneral disorders | 1/3 | 1/3 | 2/3 | 12/23 |
| Age, Categorical(Participants) | Alvocidib 20/30 mg/m2 | Alvocidib 30/40 mg/m2 | Alvocidib 30/50 mg/m2 | Alvocidib 30/60 mg/m2 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 3 | 23 | 32 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Alvocidib 20/30 mg/m2 | Alvocidib 30/40 mg/m2 | Alvocidib 30/50 mg/m2 | Alvocidib 30/60 mg/m2 | Total |
|---|---|---|---|---|---|
| Female | 2 | 2 | 1 | 9 | 14 |
| Male | 1 | 1 | 2 | 14 | 18 |
| Race (NIH/OMB)(Participants) | Alvocidib 20/30 mg/m2 | Alvocidib 30/40 mg/m2 | Alvocidib 30/50 mg/m2 | Alvocidib 30/60 mg/m2 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 2 | 5 |
| White | 1 | 1 | 2 | 20 | 24 |
| More than one race | 0 | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Mar 2020, 29 months.
Results were first posted in May 2021, 1 year 2 months after primary completion.
Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 29 months is below that.
Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alvocidib · Cytarabine · Daunorubicin
Sumitomo Pharma America, Inc. →